Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986142 effect on oral contraceptives
NCT02832180Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- May 2016
- Primary completion
- Oct 2016
- Countries
- 1
01
Overview
Phase 1, open-label trial of BMS-986142 in rheumatoid arthritis (RA) (2 arms), sponsored by Bristol Myers Squibb. Primary endpoints: Maximum observed plasma concentration of ethinyl estradiol and norethindrone acetate, Area under the concentration-time curve of ethinyl estradiol and norethindrone acetate and 1 more. Started May 2016; status: completed.
02
Drugs
BMS-986142
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02832180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02832180.